VJET

Catheter Precision, a subsidiary of Flyte Aviation (NYSE American: VJET), published a peer-reviewed study in The Journal of Interventional Cardiology demonstrating that its LockeT suture retention device outperforms Abbott's Perclose vascular closure device. The 172-patient study showed LockeT achieved 1.2% access-site complications versus 9.3% for Perclose, with zero device failures compared to 4.7% for Perclose, while maintaining equivalent efficiency in hemostasis and same-day discharge rates.

Flyte Aviation (NYSE American: VJET) reported record Q3 2026 preliminary revenue of $2.15 million, up 110% quarter-over-quarter, with aviation segment revenue increasing 150% sequentially to $1.87 million. The company's redesigned digital booking platform surged 185% in user base to over 20,000 users since its May 2026 launch, generating over $500,000 in direct-to-consumer revenue in Q3. The company is expanding its fleet, entering Caribbean operations, and pursuing Canadian expansion.